

Amendment to the Claims

1-33. (canceled)

34. (currently amended) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises: ~~a)~~ a light chain variable region and a heavy chain variable region, wherein;

the light chain variable region comprises:

~~i)~~ a CDRL1 amino acid sequence ~~selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5;~~

~~ii)~~ a CDRL2 amino acid sequence ~~selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13; and~~

~~iii)~~ a CDRL3 amino acid sequence ~~selected from the group consisting of SEQ ID NO:17, SEQ ID NO:19, and SEQ ID NO:21;~~

~~iv)~~ an FRL1 amino acid sequence consisting of SEQ ID NO:71;

~~v)~~ an FRL2 amino acid sequence consisting of SEQ ID NO:72;

~~vi)~~ an FRL3 amino acid sequence consisting of SEQ ID NO:73; and

~~vii)~~ an FRL4 amino acid sequence consisting of SEQ ID NO:74.

~~b)~~ a said heavy chain variable region, wherein the heavy chain variable region comprises:

~~i)~~ a CDRH1 amino acid sequence ~~selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:25;~~

~~ii)~~ a CDRH2 amino acid sequence ~~selected from the group consisting of SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, and SEQ ID NO:39; and~~

~~—iii) a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, and SEQ ID NO:57;~~

~~—iv) an FRH1 amino acid sequence consisting of SEQ ID NO:79;~~

~~—v) an FRH2 amino acid sequence consisting of SEQ ID NO:80;~~

~~—vi) an FRH3 amino acid sequence consisting of SEQ ID NO:81; and~~

~~—vii) an FRH4 amino acid sequence consisting of SEQ ID NO:82.~~

35-39. (canceled)

40. (withdrawn-currently amended) A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises ~~a~~ a light chain variable region and a heavy chain variable region, wherein;

the light chain variable region comprises:

~~—i) a CDRL1 amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5;~~

~~—ii) a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13; and~~

~~—iii) a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:19, and SEQ ID NO:21;~~

~~—iv) an FRL1 amino acid sequence consisting of SEQ ID NO:71;~~

~~—v) an FRL2 amino acid sequence consisting of SEQ ID NO:72;~~

~~—vi) an FRL3 amino acid sequence consisting of SEQ ID NO:73; and~~

~~—vii) an FRL4 amino acid sequence consisting of SEQ ID NO:74.~~

~~b) a said heavy chain variable region, wherein~~ the heavy chain variable region comprises:

~~—i) a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:25;~~

~~—ii) a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, and SEQ ID NO:39; and~~

~~—iii) a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, and SEQ ID NO:57;~~

~~—iv) an FRH1 amino acid sequence consisting of SEQ ID NO:79;~~

~~—v) an FRH2 amino acid sequence consisting of SEQ ID NO:80;~~

~~—vi) an FRH3 amino acid sequence consisting of SEQ ID NO:81; and~~

~~—vii) an FRH4 amino acid sequence consisting of SEQ ID NO:82.~~

41. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.

42. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (k_{off}) for human CD20 of $5.0 \times 10^{-4} \text{ s}^{-1}$ or less.

43. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.

44. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of $2.5 \times 10^{-4} \text{ s}^{-1}$ or less.

45. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of $5.0 \times 10^{-5} \text{ M}^{-1} \text{ s}^{-1}$ or greater.

46. (withdrawn) The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.

47. (withdrawn) The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.

48. (currently amended) A ~~The~~ composition of Claim 34, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:59 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:61.

49. (new) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

- a CDRL1 amino acid sequence of SEQ ID NO:3;
- a CDRL2 amino acid sequence of SEQ ID NO:11; and
- a CDRL3 amino acid sequence SEQ ID NO:21, and

the heavy chain variable region comprises:

- a CDRH1 amino acid sequence of SEQ ID NO:23;
- a CDRH2 amino acid sequence of SEQ ID NO:31; and
- a CDRH3 amino acid sequence of SEQ ID NO:45.

50. (new) The composition of Claim 49, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:63 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:65.

51. (new) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain amino acid sequence of SEQ ID NO:67 and a heavy chain amino acid sequence of SEQ ID NO:69.